AHL
AKBA icon

Abel Hall LLC’s Akebia Therapeutics AKBA Stock Holding History

Abel Hall LLC’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86K Buy
+75,438
New +$89.8K 0.01% 854
2025
Q4 		– Sell
-10,500
Closed -$28.7K – 715
2025
Q3 		$28.7K Sell
10,500
-118
-1% -$393 0.01% 310
2025
Q2 		$38.6K Buy
+10,618
New +$29.2K 0.02% 261

Other funds holding AKBA

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
PWP
Parkwoods Wealth Partners Syracuse, New York $622M AUM 24.36% 1-Year Est. Return
OBWG
Onyx Bridge Wealth Group Tarrytown, New York $1.11B AUM 24.65% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
UIM
Unified Investment Management Atlanta, Georgia $108M AUM 26.38% 1-Year Est. Return

Abel Hall LLC's AKBA Position: Q2 2026 in Review

Abel Hall LLC opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 75,438 shares worth $86K. The stake represents 0.01% of the portfolio and ranks #854 among its holdings. This is a return to the name: Abel Hall LLC previously reported a position in AKBA as recently as Q3 2025.

Abel Hall LLC first reported a position in AKBA in Q2 2025 and has held it in 3 quarters since. 28 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Abel Hall LLC held 75,438 shares of Akebia Therapeutics worth $86K as of Q2 2026.
  • Akebia Therapeutics was a new Abel Hall LLC position in Q2 2026.
  • Akebia Therapeutics made up 0.01% of Abel Hall LLC's portfolio in Q2 2026, its #854 holding.
  • Abel Hall LLC first reported a position in Akebia Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 28 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.